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ABSTRACT
Background:
The Canadian prospective randomized NCIC SR2 trial tested the
sequence of radiation and surgery for extremity soft-tissue
sarcoma. The trial was conducted in the era before intensity-
modulated radiation therapy (IMRT) was clinically available.
Similar disease control after preoperative and postoperative non-
IMRT was found. However, the preoperative non-IMRT arm
showed significantly less (persisting) late-term effects but
increased (transient) wound complication rates compared to
the postoperative non-IMRT arm (35% vs. 17%, P = 0.01).
Consequently based on these results, preoperative radiation
therapy was considered the preferred approach. Currently IMRT,
with its option for highly conformal dose distribution that
translates into better normal tissue sparing, is used as the general
standard for sarcoma radiation therapy in most patients. Our
hypothesis was that a lower wound complication rate after
preoperative radiation therapy might be achievable in the
IMRT era.
Methods:
We prospectively assessed our preoperative IMRT cohort (n= 67
consecutive patients) treated between March 2008 and March
2016 with respect to wound complication rates.
Results:
Fourteen of 67 (21%) externally referred patients with recurrent
(n=1) or incompletely resected disease (n=13), and 53 treatment-
naive patients underwent planned preoperative radiation after core
biopsy. After mean/median 7.3/7wk (3-12wk), complete tumor
resection was performed. Secondary revision was required in five of
67 (i.e., wound complication rate of 7%). Two local failures were
observed so far.
Conclusions:
The presented results support our hypothesis that preoperative
IMRT may lead to a reduced wound complication rate compared
to that after postoperative and mainly preoperative non-IMRT
techniques.
Key Words
IMRT, soft-tissue sarcoma, preoperative highly conformal
radiation therapy, wound healing, postoperative complications
INTRODUCTION
The role of combined modality radiation therapy (RT)before or after surgery of large soft-tissue sarcoma(STS) is well established.1–3 Based on the prospectively
randomized Canadian NCIC SR2 trial,4 disease control rates
were similar after preoperative and postoperative RT, while
the rate of wound complication was higher but mostly of no
severe character in the preoperative RT arm (17 vs. 35%,
[95% CI 5–30], P = 0.01). Based on the NCIC SR2 trial results,
preoperative RT has been, in consequence, introduced as the
standard procedure for STS at the own department. Smaller
RT volumes and lower RT dose are characterizing the
preoperative RT setting in STS (50 Gy in the preoperative
versus 60-66 Gy in the postoperative setting). Postoperative
RT volumes used to be larger than preoperative RT volumes,
as surgically touched tissue, scars, and any drainage tunnels
are considered to be included into the RT volume.
Radiobiologically, lower doses and smaller RT volumes
each translate into fewer side effects. Postoperative RT
includes, in consequence, two disadvantages from an RT
perspective (higher dose, larger volume). Early RT side effects
are characterized by their early and transient appearance,
generally with complete healing after a few weeks. In
contrast, late-term RT effects tend to rise months to years
after RT completion and persist or even progress over years or
decades. In consequence, late-term effects are of much more
signiﬁcance for patients than transient early side effects.
With respect to late-term effects, the radiobiological inverse
relationship between RT dose-volume and RT effects impacts
mainly patients with large lesions.5,6 Improved quality of life
due to higher late-term tolerance after preoperative RT (i.e.,
less dose AND less RT volume!) with respect to skin
alterations, tissue edema, ﬁbrosis, bone fractures, and joint
stiffness is reported.4,7–9
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Wound complications represent early RT side effects.
Wound complication rates were found to be higher in the
lower extremity, especially in the thigh, as compared to the
upper extremity.9,10 These ﬁndings were from the historic era
without IMRT techniques. Over the past approximately 15
yr, substantial advantages in RT dose distribution were
achieved by the clinical implementation of IMRT techniques,
translating into improved normal tissue sparing with com-
parable or better tumor dose coverage.
The surgical community has not yet widely adopted the
practice of referring STS patients for preoperative RT because
of the higher wound complication rates reported during the
pre-IMRT era, and to a certain degree because of dissection on
preirradiated tissue is often thought to be more challenging.
The aim of this analysis was to assess wound complication
rates after preoperative IMRT. Our hypothesis was that
reduced wound complication rates may be achievable by
using IMRT as a preoperative RT technique.
MATERIALS AND METHODS
Informed consent was available for all patients. Ethical local
committee approval was obtained for this analysis of our
prospectively collected data set (which includes disease
control parameters, treatment parameters, and treatment
tolerance parameters).
Patients
A prospective cohort of 67 consecutive patients who were all
operated and followed by the same surgeon (BF) received
preoperative IMRT between March 2008 and March 2016 at
the Department of Radiation Oncology, University Hospital
Zurich. Exclusion criterion was previous RT at the same area.
Authors GS and CG performed RT plan contouring and double-
checking and were responsible for the dose distribution of the RT
plans. All patients underwent highly conformal preoperative RT
with 50Gy in 25 fractions, followed by complete surgical
resection. In one patient with planned R1 resection postoperative
boost radiation therapy was performed (16Gy in 8 fractions).
All included patients had conﬁrmed histopathological
diagnosis done by author BB before therapy (according to
the WHO 7th Edition classiﬁcation) either on reviewed
samples of the external excisions or on regular core biopsies.
Patient details are summarized in Table 1.
Pretreatment Procedures
After completion of primary tumor staging (CT of the lung in
all, including the abdomen in selected patients, and recent
MRI of the primary lesion in all treatment-naive patients, and
in all patients after “whoops” surgery), decisions regarding
the indication for combined modality treatment were made
at the weekly multidisciplinary sarcoma board joined by
surgeons, radiation oncologists, oncologists, diagnostic radi-
ologists, and pathologists familiar with sarcomas.
Preoperative RT
RT techniques were chosen with respect to the tumor size,
anatomic extension, and tumor location (organs at risk) to
reach optimal planning target volume (PTV) coverage while
best sparing surrounding tissues. All plans were based on
three-dimensional CT-calculations, using volumetric modu-
lated arc therapy or IMRT techniques whenever superior to
conformal three-dimensional RT techniques. This was
assessed by comparative planning. In some patients, com-
parative planning was performed to identify the technique
offering the individually best dose distribution. This so-called
“plan comparison” resulted in conformal three-dimensional
RT techniques as superior/equal approach in 19 patients with
superﬁcially located lesions (“IMRT-equivalent” dose distri-
butions). Preoperative standard total dose of 50Gy delivered
in 25 fractions (5 fractions per week) with the 95% isodose
encompassing the PTV, was delivered. The clinical target
volume (CTV) was deﬁned as follows: gross tumor volume
(GTV) with a margin of 3 cm in the longitudinal and 1.5-2
cm (−3 cm if occult disease towards a compartment border is
suspected) in the lateral direction. Peritumoral edema was
included in all directions by the CTV but not in the GTV.
Pretreatment MRI (image fusion whenever possible) was
always used for GTV/CTV deﬁnition purposes. The PTV was
deﬁned as CTV plus 0-1 cm (depending on the RT [set up
error/patient positioning and of the surrounding anatomical
structures/natural borders like bone/fascia]).
Automatic calculation of the assessed GTV, PTV, and
skin areas covered by bolus materials was provided by the
Varian Treatment Planning System (TPS Eclipse™, Version
7.3.10, Varian Medical Systems, Palo Alto, CA) volume
algorithm. Placement of large bolus material (1-cm thick-
ness) to the skin in patients with tumor expansion close to
or into the skin was applied in 62 of 67 patients (92%;
TABLE 1. Patient and disease characteristics
Parameters n
Patients 67
Age, mean, median (range) 56, 58 (19-85) years
Gender (male : female) 38 : 27
Localization
Upper leg 36
Lower leg 11
Axilla/shoulder/arm 9
Thoracal/abdominal trunk 10
Histopathological diagnosis
Lipomatous tumors, N=34 (51%)
Atypical lipomatous tumor 9
Liposarcoma,
dedifferentiated
2
Liposarcoma, myxoid 21
Liposarcoma, pleomorphic 2
Unclassified sarcomas, N=19 (28%)
Pleomorphic 17
Spindle cell 2
Myxofibrosarcoma 6
Leiomyosarcoma 3
Synovial sarcoma 3
Others (1 DFSP, 1 SEF) 2
Referred with “whoops lesions” 14 (21%)
GTV (mean, median (range) 402/261 cc (range, 0-1654 cc)
PTV (mean, median (range) 1320/1100 cc
(range, 18-3908 cc)
Bolus (mean, median (range) 129/102 cc (range, 15-600 cc)
DFSP, dermatofibrosarcoma protuberans; GTV, gross tumor volume; PTV,
planning target volume; SEF, sclerosing epithelioid fibrosarcoma.
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Table 1). The use of bolus materials aims to intentionally
increase the dose to the covered skin towards full
prescription dose instead of the lower entry dose achieved
without bolus; this translates clinically into expectedly
increased early skin reaction. The biopsy canal was covered
with a small bolus to sufﬁciently treat potential micro-
scopic spread due to previous biopsy.
Surgical Treatment
Surgery was performed 6 to 8wk after completion of RT in 65
patients. Treatment delay occurred in two patients because of
unrelated medical problems: one patient experienced a
myocardial infarction after he received 40Gy in 2.0 Gy/
fraction and required a percutaneous coronary intervention
with a stent implantation. He recovered well and was
operated at 10 wk after the completion of the RT without
any symptoms but with continuous aspirin medication;
another patient’s surgery was delayed due to the patient’s
preference. Preoperatively, all patients received at least three
doses of cefuroxime intravenously. The surgical technique
included resection of all macroscopic tumor in an en bloc
fashion, including previous biopsy scars and drain sites, if
present. The aim was to spare neurovascular structures with
the principles established by the Toronto group, taking
advantage of the biological barriers to accept close margins.11
The sciatic nerve was preserved by entering the perineurium
of the sciatic nerve proximally and distally of the tumor such
that the perineurium was left with the tumor. Accordingly,
the adventitia as well as the periosteum, if necessary, were
dissected from the vascular structures and bone, respectively,
and left with the tumor. In case of no biological barrier, we
chose a 1- to 2-cm radial margin and longitudinally 4 to 5 cm.
Special care was taken to achieve meticulous hemostasis
during the entire surgery. Drains were routinely used and
removed depending on ﬂuid production usually between 24-
48 hr after surgery. In patients who were referred to our
institution after prior incomplete tumor excision, careful re-
excision of the surgical bed and scar was performed. Wound
complications were deﬁned according to the Canadian Trial
as requiring secondary operations or invasive procedures for
wound care, use of vacuum-assisted closure, prolonged
dressing changes, or infection within 120 days of surgery.4
The follow-up of all patients was regularly performed by
author BF (surgeon) initially according to the healing process
and the extent of surgery and after some weeks every 3mo
during the ﬁrst 2 yr after treatment, then twice a year. All
surviving patients are still in regular follow-up.
Statistics
Survival curves were performed using Kaplan Meier calculations
[StatView® (Version 4.5; SAS Institute, Cary, NC, USA)].
RESULTS
Wound Complication Rate
At the time of surgery at a mean/median time of 7.3/7 wk
after RT, none or mild residual early dermatitis was seen in all
patients (grade 0-2 skin reaction according to CTCA Ev3).
Sixty-two of 67 (93%) patients experienced uneventful
primary wound closure. Secondary revision was required in
ﬁve of 67 patients (wound complication rate 7%). In three of
these ﬁve affected patients, the tumor was located in the
adductor muscle compartment. In the remaining two
patients with initially uneventful healing, secondary wound
breakdown without an apparent reason required revision.
Regarding the skin exposed to tumor dose in the ﬁve
patients with wound complications, the skin area covered by
bolus material was mean/median 207/182 cc, range 81 cc to
400 cc (higher values than the patients without wound
complications with mean/median 138/119 cc, range 16 to
600; no statistics: unbalanced sample size). Also the GTV was
mean/median larger in the affected ﬁve patients compared to
unaffected individuals (510/402 cc, range 32 to 1380 cc vs.
396 to 294 cc, range 0 to 1654 cc).
Preoperative radiation allowed closer surgical margins to
spare functionally important structures in the majority of
patients according to the principles established by the Toronto
group.3,11–15 A safe biologic margin depends not only on the
metric distance, but also on the biologic barrier. Close
histopathologic metric margins were chosen depending on
the type of biologic barrier and were as follows in this series: 0
to 1mm in 40 of 58, 2 to 3mm in 12 of 58, 5 to 35mm in six
of 58 patients with STC; 0-3mm in nine of nine patients with
atypical lipomatous tumor (ALT) (relation to mdm2 not
necessary since included in the histopathologic deﬁnition of
ALT), one patient had a planned positive margin resection.11
Disease Control
After a mean/median follow-up time of 37/33mo (range
4-106), two local failures were observed, both in patients who
presented with prior “whoops” lesions. Local control, distant
metastasis-free survival, and overall survival rates for the 58
patients with malignant sarcoma (nine patients with atypical
lipomatous histologies excluded) at 3 yr were 98%, 69% and
86%, respectively. Forty-ﬁve patients with high-grade sarco-
ma referred for primary treatment were all locally controlled
(without any signs of local recurrence on MRI) when last
seen. Nine of 67 patients diagnosed with ALT were
interdisciplinarily decided to undergo combined modality
treatment because of the large tumor size and/or close
contact to the neurovascular bundle.
DISCUSSION
We found a wound complication rate of 7% in the presented
cohort, and a local control rate of 100% in treatment-naive
patients with preoperative IMRT for STS. The low wound
complication rate found in our cohort was lower than the
postoperative and mainly the preoperative non-IMRT arm of
the Canadian prospective randomized NCIC SR2 trial (7% vs.
17% and 35%, respectively),4 supporting our hypothesis.
In our department the publication of the NCIC SR2 trial
results4 led to an internal standard operation procedure change
to preoperative RT. IMRT was used early after clinical imple-
mentation back in 2003. Our satisfactory interdisciplinarily
achieved results motivated to the constitution of our sarcoma
center and to the release of our national STS guidelines.16
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Limitations of our analysis include the relatively small
sample size and with respect to the disease control a still
short follow-up time. Nevertheless, our results point
towards a lower wound complication rate in a well-deﬁned,
single-center group of patients who were all homogene-
ously treated according to the same protocol by the same
physicians.
In our patients with wound complications, a larger skin
area with tumor dose was found as compared to the patients
without wound complications. Baldini et al.17 found tumor
size and (often positively related) proximity to the skin to be
signiﬁcant predictors for major wound complications in
univariate analyses. There are several other reports on wound
complications after non-IMRT series. Tseng et al.10 reported a
wound complication rate of 36% for the lower extremity in a
collective of 49 patients. These authors found no difference
in terms of wound complication rates whether the primary
surgeon or a reconstructive surgeon performed the wound
closure. Cannon et al.18 reported a wound complication rate
of 34% for resection after preoperative RT of the lower
extremity, applying the same deﬁnitions for wound compli-
cations as O’Sullivan et al.4 after preoperative RT and tumor
resection of the lower limb.
Preoperative (IMRT or non-IMRT) radiation therapy is
favored by others because it uses less irradiation volume und
dose, with potentially fewer long-term side effects for the
patients. Virkus et al.2 reported a wound complication rate of
26% after preoperative (conventional three-dimensional, i.e.
non-IMRT) RT and surgical resection in the lower extremity.
The authors considered wound complications as moderate
when wounds required an operative irrigation and debride-
ment with reclosure or wounds that had not closed after
3 months of local treatment, major when multiple operative
interventions were necessary, and amputation as a third class
of wound complications. Cheng et al.19 compared preoper-
ative with postoperative non-IMRT radiation and reported a
wound complication rate of 31% in the preoperative
compared to 8% in the postoperative subgroup (wound
complication deﬁned as any wound problem that required a
secondary operation for treatment, resulted in a delay in RT
of at least 1mo, or a wound that did not heal and persisted
for at least 6mo). They did not report separate results for
tumors of the upper and lower extremities. Mack et al.20
assessed 75 patients also from the pre-IMRT era who received
a shorter-course preoperative RT (30 Gy in fractions of 3.0 Gy
per day in 10 days) combined with neoadjuvant chemo-
therapy and reported a wound complication rate of 16%.
They considered a wound complication as major when a
patient needed a reoperation and as minor when a patient
developed a seroma, infection, or minor wound breakdown
that could be treated by local wound care, antibiotics, or
drainage. No separate report on complication rates for the
upper extremity was given; however, the collective consisted
of 73% of patients with tumors of the lower extremity.
Overall, the wound complications in these series of preop-
erative RT ranged between 16% and 36%. Our result of 7% of
wound complications compares favorably but is still lower
than any reported. The type of RT used may be one
explanation for the relatively high complication rate in
these older series, and IMRT may improve it. Alektiar et al.21
presented preliminary results on preoperative or postoper-
ative IMRT of upper and lower extremity STS in 31 patients
and found infectious and noninfectious wound complication
rates of 13% and 10%, respectively. A recent phase-2 study
performed by the Canadian trialists on wound complication
rates of lower extremity STS showed no signiﬁcant difference
in wound complication rates after preoperative IMRT
compared with non-IMRT in the NCIC trial (30.5 vs. 43%,
P = 0.6).22 Therefore, the authors speculated that IMRT
alone may not represent the main factor inﬂuencing wound
complications. Wang et al.23 reported the results of the
TROG-0630 Trial (extremity STS treated with image-guided
RT to a reduced target volume, with preoperative IMRT in
75% of 79 eligible patients). Thirty-six percent (26/71
patients assessed for wound complications) experienced at
least one wound complication (secondary operative debride-
ment [25.5%], prolonged dressing changes [24%], readmis-
sion for wound care [21%]).23
Other reasons also may negatively affect wound compli-
cations. The interval to perform surgery after the last
radiation treatment may be important. Whereas the group
from Toronto found a trend towards a higher rate of wound
complications in patients who had surgery after 6 wk (28%
prior vs. 34% after; P < 0.08), this was not found in our
results, with a mean interval of 7.3 wk and a wound
complication rate of 7%; however, our small sample size
and wound complication rates prevent forming reliable
information on this topic.3 Tumor localization may also
be a predictor of wound breakdown,24 with tumors in the
adductor compartment of the thigh speciﬁcally being
associated with wound break down. This also was conﬁrmed
by our series, with the tumor in four of ﬁve patients with
wound complications being localized in the thigh.
The international community may deﬁne parameters such
as size, volume, response to RT, etc. such that large patient
numbers from different centers become comparable and
small differences can be identiﬁed. One aspect to be kept in
mind in preoperative sarcoma RT is certainly the often seen
tumor volume change under RT,25 requiring adaptive
planning in certain patients (performed in two of 67 of our
patients). It has been shown that the outcome of patients
with STS indeed does differ even among international high-
volume centers.26,27
In conclusion the presented results support our hypothesis
that preoperative IMRT may lead to a reduction of wound
complication rates compared to that after postoperative and
mainly preoperative non-IMRT techniques.
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